LncRNA | Differential expression in ovarian carcinoma | Clinical application | References |
---|---|---|---|
HOTAIRa | Up | HOTAIR levels were positively correlated with the FIGO stage, histological grade of the tumor, lymph node metastasis. HOTAIR was an independent prognostic factor for OS and DFS in ovarian cancer patients | |
HOXA11-ASa | Down in EOC | High HOXA11-AS in SOC expression in tumor tissues was an independent predictor of poor PFS and OS | |
Up in SOC | |||
Xista | Down | Reduced expression of Xist in patient samples was correlated with a shorter progression-free interval | |
ANRILa | Up | Elevated ANRIL expression was positive correlated with advanced FIGO stage, high histological grade, lymph node metastasis. ANRIL was an independent prognostic factor for OS. | |
MEG3a | Down | No evidence | |
HOST2a | Up | No evidence | [64] |
FAL1a | Up | FAL1 occurred frequently in epithelial cancer and were associated with clinical outcomes in patients with ovarian cancer | [65] |
LSINCT5a | Up | No evidence | [66] |
ZNF300P1a | Down | No evidence | [67] |
TC1500845, TC0901107 | Up | No evidence | [68] |
TC0100223, TC0101686 | Down | No evidence | |
TC0101441a | Up | TC0101441 was an independent prognostic factor for OS in ERα-positive ovarian cancer | |
AB073614a | Up | 5-year OS in ovarian cancer patients with high expression of AB073614 was inferior to that with low expression | [73] |
ASAP1-IT1 | Up | High expression of ASAP1-IT1 and FAM215A were associated with favorable OS | [74] |
FAM215A | Up | ||
PVT1a | Up | Low expression levels of PVT1 and lnc-SERTAD2–3 exhibited longer PFS and OS. PVT1, lnc-SERTAD2–3 and hsa-miR-200c-3p simultaneously can stratify patients’ risk of relapse into three discrete classes, high risk, mixed and low risk | [60] |
lnc-SERTAD2–3 | Up | ||
RP11-284Â N8.3.1 | Down | RP11-284Â N8.3.1 and AC104699.1.1 significantly divide stages III and IV ovarian cancer patients into high- and low-risk groups and their increased expressions were associated with a decreased risk of survival | [77] |
AC104699.1.1 | Down | ||
AC005562.1, AC105760.2, EPB41L4A-AS1, MCM3AP-AS1 | Up | Potential candidates associated with stage progression in ovarian cancer and could classify patients into high-and low-risk subgroups with significantly different survival outcomes | [81] |
AC074117.10, MEG8, RP11-220I1.1, RP11-429Â J17.2, RP11-618G20.1 | Down | ||
AC092214.10, CYP3A5, LEMD1, PART1, RNF157-AS1, RP11-532F12.5 | Up | No evidence | [83] |
AC010680.1, ADAMTS9-AS1, ADAMTS9-AS2, AK021537, AK125532, GRTP1-AS1, LEMD1-AS1, LOC386758, LOC729970, RP1–7814.1, RP11-597D13.9, LEMD1-AS1 | Down | ||
lnc-SOX4–1, lnc-HRCT1–1 | Up | Low expression levels of lnc-SOX4–1 and lnc-HRCT1–1 exhibited longer PFS and OS | [60] |
RUNX1-IT1, MALAT1 | Up | RUNX1-IT1, MALAT1, H19, HOTAIRM1, LOC100190986 and AL132709.8 were associated with OS and DFS | [49] |
H19a | Majority expressed in benign, borderline and invasive SOC, but not in epithelial cells of the mucinous tumors | ||
HOTAIRM1, LOC100190986, AL132709.8 | Up | ||
SPRY4-IT1 | Up | High lncRNA SPRY4-IT1 expression is an independent prognostic factor for PFS and OS | [85] |
BC037530, AK021924, AK094536, AK094536, BC062365 | Up | Higher expressions of lncRNAs BC037530, AK021924, AK094536, AK094536, BC062365 and lower expressions of lncRNAs BC004123Â BC007937 were associated with ovarian cancer patients survival and can serve as an independent predictor apart from FIGO stage and patient grade | [86] |
BC004123, BC007937 | Down | ||
LOC100288181 | Up | High Lnc-OC1 expression was associated with poor prognosis of ovarian cancer patients | [87] |
DUXAP10 | Up | The overall survival of patients with ovarian cancer whose DUXAP10 was overexpressed was significantly lower than that in the DUXAP10 low expression group. Tumor stage in DUXAP10 high expression group was higher, and the tumor volume was larger. | [88] |